Vilches Joseph R, Taylor Mackenzie B, Filbey Francesca M
Center for BrainHealth, School of Behavioral and Brain Sciences, University of Texas at Dallas, Dallas, TX, United States.
Department of Psychology, University of North Texas, Denton, TX, United States.
Front Psychiatry. 2021 Jan 14;11:624012. doi: 10.3389/fpsyt.2020.624012. eCollection 2020.
With the passing of the 2018 Agriculture Improvement Act that legalized hemp-derived products, i.e., cannabidiol (CBD), the use of CBD has increased exponentially. To date, the few studies that have characterized individuals who use CBD suggest that co-use of CBD and tetrahydrocannabinol (THC)-dominant cannabis, i.e., marijuana, is highly prevalent. It is, therefore, important to investigate the relationship between CBD use and marijuana use to understand the antecedents and consequences of co-use of these two cannabis products. We conducted an online survey using structured questionnaires to determine differences in CBD users with (CBD+MJ) and without co-morbid marijuana use. Group comparisons were carried out using chi-square tests and ANOVA. Multiple correspondence analysis (MCA) with bootstrap ratio testing was performed to examine the relationship between the categorical data. We received 182 survey responses from current CBD users. CBD+MJ had more types of CBD administration ( = 17.07, < 0.001) and longer lifetime duration of CBD use (χ2 = 12.85, < 0.05). Results from the MCA yielded two statistically significant dimensions that accounted for 77% of the total variance. Dimension 1 (representing 57% of the variance) associated CBD+MJ with indication of CBD use for medical ailments, use of CBD for more than once a day for longer than 2 years, applying CBD topically or consuming it via vaping or edibles, being female, and, having lower educational attainment. Dimension 2 (representing 20% of the variance) separated the groups primarily on smoking-related behaviors where CBD+MJ was associated with smoking CBD and nicotine. Identifying the factors that influence use of CBD and marijuana can inform future studies on the risks and benefits associated with each substance as well as the impacts of policies related to cannabis-based products.
随着2018年《农业改进法案》的通过，该法案使源自大麻的产品（即大麻二酚（CBD））合法化，CBD的使用呈指数级增长。迄今为止，少数针对使用CBD的人群进行特征描述的研究表明，CBD与以四氢大麻酚（THC）为主的大麻（即大麻）共同使用的情况非常普遍。因此，研究CBD使用与大麻使用之间的关系，以了解这两种大麻产品共同使用的前因后果，具有重要意义。我们使用结构化问卷进行了一项在线调查，以确定有（CBD+MJ）和无共病大麻使用的CBD使用者之间的差异。使用卡方检验和方差分析进行组间比较。进行了带有自举比率检验的多重对应分析（MCA），以检验分类数据之间的关系。我们收到了来自当前CBD使用者的182份调查回复。CBD+MJ组有更多类型的CBD给药方式（ = 17.07， < 0.001），且CBD使用的终生时长更长（χ2 = 12.85， < 0.05）。MCA的结果产生了两个具有统计学意义的维度，占总方差的77%。维度1（占方差的57%）将CBD+MJ与用于医疗疾病的CBD使用指征、每天使用CBD超过一次且持续超过2年、局部涂抹CBD或通过雾化或食用方式摄入CBD、女性以及教育程度较低相关联。维度2（占方差的20%）主要根据与吸烟相关的行为将两组分开，其中CBD+MJ与吸食CBD和尼古丁相关。确定影响CBD和大麻使用的因素，可以为未来关于每种物质相关的风险和益处以及与大麻基产品相关政策的影响的研究提供信息。
